Abstract:Di‐methylation of CD147 at Lys148 (CD147‐K148me2) mediated by the methyltransferase NSD2 is a common post‐translational modification in non‐small cell lung cancer (NSCLC), which values significantly in unsatisfactory survival outcomes among NSCLC sufferers. This modification promotes the CyPA‐CD147 interaction and in turn increases NSCLC cell‐derived CCL5 secretion by activating p38‐ZBTB32 signaling, which facilitates M2‐tumor‐associated macrophage infiltration in NSCLC tissues via the CCL5/CCR5 axis. Targeting CD147‐K148me2 is a promising therapeutic strategy for NSCLC. Immunosuppression is a major hallmark of tumor progression in non‐small cell lung cancer (NSCLC). Cluster of differentiation 147 (CD147), an important pro‐tumorigenic factor, is closely linked to NSCLC immunosuppression. However, the role of CD147 di‐methylation in the immunosuppressive tumor microenvironment (TME) remains unclear. Here, di‐methylation of CD147 at Lys148 (CD147‐K148me2) is identified as a common post‐translational modification (PTM) in NSCLC that is significantly associated with unsatisfying survival outcomes among NSCLC sufferers, especially those in the advanced stages of the disease. The methyltransferase NSD2 catalyzes CD147 to generate CD147‐K148me2. Further analysis demonstrates that CD147‐K148me2 reestablishes the immunosuppressive TME and promotes NSCLC progression. Mechanistically, this modification promotes the interaction between cyclophilin A (CyPA) and CD147, and in turn, increases CCL5 gene transcription by activating p38‐ZBTB32 signaling, leading to increased NSCLC cell‐derived CCL5 secretion. Subsequently, CD147‐K148me2‐mediated CCL5 upregulation facilitates M2‐like tumor‐associated macrophage (TAM) infiltration in NSCLC tissues via CCL5/CCR5 axis‐dependent intercellular crosstalk between tumor cells and macrophages, which is inhibited by blocking CD147‐K148me2 with the targeted antibody 12C8. Overall, this study reveals the role of CD147‐K148me2‐driven intercellular crosstalk in the development of NSCLC immunosuppression, and provides a potential interventional strategy for PTM‐targeted NSCLC therapy.

Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells

CD147 Depletion Down-Regulates Matrix Metalloproteinase-11, Vascular Endothelial Growth Factor-a Expression and the Lymphatic Metastasis Potential of Murine Hepatocarcinoma Hca-F Cells.

CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells.

Expression of CD147 in Advanced Non-Small Cell Lung Cancer Correlated with Cisplatin-Based Chemotherapy Resistance.

A Small Interfering CD147-Targeting RNA Inhibited the Proliferation, Invasiveness, and Metastatic Activity of Malignant Melanoma

[Rnai-Mediated Silencing of CD147 Inhibits the Proliferation and Infiltrations of Leukemic Cells SHI-1].

Inhibition Of Cd147 Gene Expression Via Rna Interference Reduces Tumor Cell Invasion, Tumorigenicity And Increases Chemosensitivity To Cisplatin In Laryngeal Carcinoma Hep2 Cells

RNA interference targeting extracellular matrix metalloproteinase inducer (CD147) inhibits growth and increases chemosensitivity in human cervical cancer cells.

CD147 Regulates Vascular Endothelial Growth Factor-a Expression, Tumorigenicity, and Chemosensitivity to Curcumin in Hepatocellular Carcinoma.

Involvement of CD147 in Regulation of Multidrug Resistance to P‐gp Substrate Drugs and in Vitro Invasion in Breast Cancer Cells

Expression of Cd147 Mediates Tumor Cells Invasion and Multidrug Resistance in Hepatocellular Carcinoma

Silencing of CD147 inhibits cell proliferation, migration, invasion, lipid metabolism dysregulation and promotes apoptosis in lung adenocarcinoma via blocking the Rap1 signaling pathway

Inhibition of Cd147 Gene Expression Via Rna Interference Reduces Tumor Cell Proliferation, Activation, Adhesion, and Migration Activity in the Human Jurkat T-Lymphoma Cell Line

Extracellular matrix metalloproteinase inducer (CD147/BSG/EMMPRIN)-induced radioresistance in cervical cancer by regulating the percentage of the cells in the G2/m phase of the cell cycle and the repair of DNA Double-strand Breaks (DSBs).

Targeting CD147 is a Novel Strategy for Antitumor Therapy

ResearchRNAi-mediated silencing of CD 147 inhibits tumor cell proliferation , invasion and increases chemosensitivity to cisplatin in SGC 7901 cells in vitro

CD147-targeted Sirna in A375 Malignant Melanoma Cells Induces the Phosphorylation of EGFR and Downregulates Cdc25c and MEK Phosphorylation.

LINC00662 Promotes Melanoma Progression by Competitively Binding Mir-107 and Activating the Β-Catenin Signaling Pathway.

Downregulation of CD 147 Expression by RNA Interference Inhibits HT 29 Cell Proliferation , Invasion and Tumorigenicity in Vitro and in Vivo

RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro

CD147‐K148me2‐Driven Tumor Cell‐Macrophage Crosstalk Provokes NSCLC Immunosuppression via the CCL5/CCR5 Axis